TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease.
The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing).
The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities.
TapImmune is conducting clinical trials and R&D programs, to explore the promising commercial potential of our comprehensive approach to immunotherapy that stimulates Helper T-cells; Killer T-cells and enhances antigen presentation.
This all-encompassing approach makes TapImmune a leading innovator and world class immunotherapy company.